Beloranib, an analog of the natural chemical compound fumagillin, is an inhibitor of the enzyme METAP2. It was originally designed as angiogenesis inhibitor for the treatment of cancer.
Beloranib, or ZAFGEN, an analog of the natural chemical compound fumagillin, is an inhibitor of the enzyme METAP2. It was originally designed as angiogenesis inhibitor for the treatment of cancer.
I know a lot of people are really looking forward to receiving chemotherapy so that they can lose weight. Sheesh.
Awesome job Eisai! Get those extra reps going for December!
ZAFGEN is basically chemotherapy! Look it up! Yeah a lot of cancer patients lose weight when receiving chemotherapy. Not very pleasant that's for sure.
More important, that is at least 5 years off!
Buy hand over fist. Arena's future has been all but guaranteed with the most recent developments. $250M in cash, no debt, big partner with deep pockets, promising pipeline addressing serious health issues today.
I just love trading this stock. Ups and downs are guaranteed. 25% to 50% gains are a given! $1.96 to $2.95 almost 50% gain in just a few weeks! Wowsa!
Agreed. Arena's future is all but confirmed as bright with recent milestones and RoW rights to Eisai. Arena may now develop the pipeline without hesitation. Full steam ahead.
Finally an upgrade after years of waiting!
Again my calculator keeps coming up with a fair market value of $2.25B or $10.25 per share with $250 million in cold hard cash in bank in hand and no debt. QCOR with one product and $250 million in bank valued now at $3.5B. QCOR does not have a pipeline people! ARNA does!
Yes they will double the float to survive an additional 6 to 7 years until product on the market. Those exec salaries have to be maintained at any cost.
Sorry but that is the cost. Dilution is all but guaranteed here. Product is now at least 6 years out.
I believe $8 is the target. Market cap too too rich at $450 million. Needs to be $300 million now with only one drug candidate.
It will cost $250 million to $500 million, take 1 year to work out details with FDA, 2-3 years more to enroll and complete study. Another year to apply for approval, another year to review data and set up AdCom, another year for PDUFA. Earliest will be 2020.
Sorry. This is a buy at $8.
My target is $8 entry. Although I may grab some at $12 for a quick pop to $15 on a dead cat bounce.
Arena going to $8 shortly and then $10 for a fair market value of $2.25 billion.
That's what I have been hearing over the past year. Take a look at the 1 year chart and see for yourself what the pattern is.
Please refer to my previous posts. With $250M in bank, no debt, and steady stream of revenue coming in, ARNA should have a fair market value of $2.25B or $10.25 per share.
Only on their tax forms and nowhere else. I know from personal experience.
Nothing GALE has now justifies a market cap of $750 million. Nothing. Triple? Maybe just before PIII completed iin 2017.
At most I see a maximum of $5 which is great!